Literature DB >> 22358357

Detection of genomic mutations in katG, inhA and rpoB genes of Mycobacterium tuberculosis isolates using polymerase chain reaction and multiplex allele-specific polymerase chain reaction.

Azar Dokht Khosravi1, Hamed Goodarzi, Seyed Mohammad Alavi.   

Abstract

OBJECTIVE: Isoniazid (INH) and rifampin (RIF) are the most effective first line antibiotics against Mycobacterium tuberculosis. Mutations in several genes determine resistance of M. tuberculosis to INH, with the most common gene target of katG, and resistance to RIF is due to mutation in rpoB gene. The aim of present study was to assess the mutations in the regions related to RIF and INH resistance.
METHODS: We characterized 80 clinical isolates of confirmed M. tuberculosis to analyze the most commonly observed INH and RIF mutations. PCR analysis and sequencing were used to detect mutations related to RIF and INH resistance. The multiplex allele-specific-PCR (MAS-PCR) was performed as a comparative assay and for evaluation of this method.
RESULTS: The sequencing of the 250-bp region of katG codon 315, revealed point mutations at 5 different codons in 13.7% of the M. tuberculosis isolates. The sequencing of the 270-bp central region of the rpoB gene revealed point mutations at 7 different codons in 12 (15%) of the M. tuberculosis isolates. The results obtained with MAS-PCR are in accordance with PCR-sequencing with high sensitivity and specificity for katG315, inhA15, and rpoB (531, 516, 526).
CONCLUSION: The results of this study suggested that molecular techniques can be used as a rapid tool for the identification of drug resistance in clinical isolates of M. tuberculosis. Both DNA sequencing and MAS-PCR yielded high sensitivity for the detection of RIF and INH mutations and detecting multi-drug resistant tuberculosis cases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22358357     DOI: 10.1016/s1413-8670(12)70275-1

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  7 in total

1.  An effective nano drug delivery and combination therapy for the treatment of Tuberculosis.

Authors:  Mojgan Sheikhpour; Vincent Delorme; Alibakhsh Kasaeian; Vahid Amiri; Morteza Masoumi; Mohammad Sadeghinia; Nayereh Ebrahimzadeh; Mobina Maleki; Shahin Pourazar
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

2.  Evaluation of the frequency of resistance to 2 drugs (Isoniazid and Rifampin) by molecular investigation and it's risk factors in new cases of smear positive pulmonary tuberculosis in health centers under the cover of Jundishapur University of Medical Sciences in 2017.

Authors:  Shokrollah Salmanzadeh; Masoumeh Karamian; Seyed Mohammad Alavi; Roohangiz Nashibi
Journal:  J Family Med Prim Care       Date:  2020-04-30

3.  Evaluation of gene mutations involved in drug resistance in mycobacterium tuberculosis strains derived from tuberculosis patients in mazandaran, iran, 2013.

Authors:  Farhang Babamahmoodi; Mohammad Reza Mahdavi; Hossein Jalali; Bita Talebi; Payam Roshan; Mehrad Mahdavi
Journal:  Int J Mol Cell Med       Date:  2014

4.  Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.

Authors:  Lisa Nkatha Micheni; Kennedy Kassaza; Hellen Kinyi; Ibrahim Ntulume; Joel Bazira
Journal:  PLoS One       Date:  2021-10-29       Impact factor: 3.240

5.  Detection and characterization of mutations in genes related to isoniazid resistance in Mycobacterium tuberculosis clinical isolates from Iran.

Authors:  Pejman Bakhtiyariniya; Azar Dokht Khosravi; Mohammad Hashemzadeh; Mohammad Savari
Journal:  Mol Biol Rep       Date:  2022-04-02       Impact factor: 2.742

6.  Genetic diversity of drug-resistant Mycobacterium tuberculosis clinical isolates from Khuzestan province, Iran.

Authors:  Pejman Bakhtiyariniya; Azar Dokht Khosravi; Mohammad Hashemzadeh; Mohammad Savari
Journal:  AMB Express       Date:  2022-07-04       Impact factor: 4.126

7.  Use of DNA microarray chips for the rapid detection of Mycobacterium tuberculosis resistance to rifampicin and isoniazid.

Authors:  Peijun Tang; Xiafang Wang; Xinghua Shen; Meihua Shi; Xuefeng Zhu; Xin Yu; Jia Liu; Chunhua Ling; Meiying Wu
Journal:  Exp Ther Med       Date:  2017-03-21       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.